CN111225672A - 甲羟戊酸通路抑制剂及其药物组合物 - Google Patents

甲羟戊酸通路抑制剂及其药物组合物 Download PDF

Info

Publication number
CN111225672A
CN111225672A CN201880066172.5A CN201880066172A CN111225672A CN 111225672 A CN111225672 A CN 111225672A CN 201880066172 A CN201880066172 A CN 201880066172A CN 111225672 A CN111225672 A CN 111225672A
Authority
CN
China
Prior art keywords
cells
tumor
group
alkyl
mevalonate pathway
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880066172.5A
Other languages
English (en)
Other versions
CN111225672B (zh
Inventor
张永辉
周晓英
肖鸿颖
夏赟
谢永华
于正森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Original Assignee
Tsinghua University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University filed Critical Tsinghua University
Publication of CN111225672A publication Critical patent/CN111225672A/zh
Application granted granted Critical
Publication of CN111225672B publication Critical patent/CN111225672B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明提供甲羟戊酸通路抑制剂在制备用于治疗和/或预防肿瘤、用于引起肿瘤细胞免疫原性死亡诱导免疫反应以及用于活化T细胞或DC细胞直接促进宿主机体免疫力的药物中的用途。本发明还提供了包含甲羟戊酸通路抑制剂和抗肿瘤药物(例如免疫检查点抑制剂和任何能够导致新抗原产生的药物)的药物组合物以及甲羟戊酸通路抑制剂与抗肿瘤药物(例如免疫检查点抑制剂和任何能够导致新抗原产生的药物)和/或放疗的联用。

Description

PCT国内申请，说明书已公开。

Claims (12)

  1. PCT国内申请，权利要求书已公开。
CN201880066172.5A 2017-10-16 2018-10-15 甲羟戊酸通路抑制剂及其药物组合物 Active CN111225672B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710962422 2017-10-16
CN2017109624220 2017-10-16
PCT/CN2018/110256 WO2019076269A1 (zh) 2017-10-16 2018-10-15 甲羟戊酸通路抑制剂及其药物组合物

Publications (2)

Publication Number Publication Date
CN111225672A true CN111225672A (zh) 2020-06-02
CN111225672B CN111225672B (zh) 2023-09-29

Family

ID=66174290

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880066172.5A Active CN111225672B (zh) 2017-10-16 2018-10-15 甲羟戊酸通路抑制剂及其药物组合物

Country Status (5)

Country Link
US (1) US20210008084A1 (zh)
EP (1) EP3698797A1 (zh)
KR (1) KR20200066690A (zh)
CN (1) CN111225672B (zh)
WO (1) WO2019076269A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114177168A (zh) * 2021-12-29 2022-03-15 诸暨市人民医院 辛伐他汀在制备预防或治疗肝癌的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195919A1 (en) * 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
US20130309270A1 (en) * 2010-10-22 2013-11-21 President And Fellows Of Harvard College Vaccines comprising bisphosphonate and methods of use thereof

Family Cites Families (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4252742A (en) 1979-07-13 1981-02-24 Ciba-Geigy Corporation Chemical process for the preparation of 2,6-dialkylcyclohexylamines from 2,6-dialkylphenols
US4348328A (en) 1981-11-09 1982-09-07 G.D. Searle & Co. 25-Substituted-5α-cholestane-3β,22S-diol
US4509612A (en) 1982-09-28 1985-04-09 Applied Power Inc. Latch mechanism for a tilt-cab truck
DE3580863D1 (de) 1984-06-04 1991-01-24 Merck & Co Inc Herstellungsverfahren von hemmstoffen der hmg-coa-reduktase mit einer 3,5-dihydroxypentanoatteilstruktur.
DE3428524A1 (de) 1984-08-02 1986-02-13 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4611068A (en) 1984-11-19 1986-09-09 Merck Frosst Canada, Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
DE3512536A1 (de) 1985-04-06 1986-10-16 Boehringer Mannheim Gmbh, 6800 Mannheim Neue diphosphonsaeure-derivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4668699A (en) 1985-08-05 1987-05-26 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
DE3540150A1 (de) 1985-11-13 1987-05-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4927851A (en) 1986-01-07 1990-05-22 Sandoz Pharm. Corp. Analogs of mevalonolactone and derivatives thereof
US4772626A (en) 1986-01-31 1988-09-20 Merck & Co., Inc. Antihypercholesterolemic compounds
US4937263A (en) 1986-05-05 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US4937264A (en) 1986-05-05 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
US4940727A (en) 1986-06-23 1990-07-10 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
PT85109A (en) 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3626058A1 (de) 1986-08-01 1988-02-11 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
DE3632893A1 (de) 1986-09-27 1988-04-07 Hoechst Ag 4-(r)-hydroxy-6(s)-arylthiomethyl-tetrahydropyran-2-one, deren entsprechende sulfoxide und sulfone, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3640938A1 (de) 1986-11-29 1988-06-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindung enthaltende arzneimittel
US4719229A (en) 1987-05-13 1988-01-12 Merck & Co., Inc. Antihypercholesterolemic agents
US4904646A (en) 1987-05-22 1990-02-27 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-COA reductase inhibitors
US5091378A (en) 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
US5017716A (en) 1987-05-22 1991-05-21 E.R. Squibb & Sons, Inc. Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method
US4885314A (en) 1987-06-29 1989-12-05 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4792614A (en) 1987-08-05 1988-12-20 American Home Products Corporation Substituted furans as inhibitors of 3-hydroxy-3-methylglutaryl-coa reductase
PT88364A (pt) 1987-09-02 1989-07-31 Merck & Co Inc Process for preparing novel hmg-coa reductase inhibitors
US4929620A (en) 1987-12-10 1990-05-29 Warner-Lambert Company 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis
US4892884A (en) 1987-12-21 1990-01-09 Rorer Pharmaceutical Corporation Novel hmg-coa reductase inhibitors
US4939143A (en) 1987-12-21 1990-07-03 Rorer Pharmaceutical Corporation Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors
US4904692A (en) 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4863957A (en) 1987-12-21 1989-09-05 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4994494A (en) 1987-12-21 1991-02-19 Rhone-Poulenc Rorer Pharmaceuticals Inc. HMG-COA reductase inhibitors
US4900754A (en) 1987-12-21 1990-02-13 Rorer Pharmaceutical Corp. HMG-COA reductase inhibitors
US4904691A (en) 1987-12-21 1990-02-27 Rorer Pharmaceutical Corporation Novel HMG-CoA reductase inhibitors
US4946864A (en) 1988-02-01 1990-08-07 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4866068A (en) 1988-02-01 1989-09-12 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
DD283612A5 (de) 1988-02-25 1990-10-17 Bayer Aktiengesellschaft,De Verfahren zur herstellung von substituierten imidazolinonen und imidazolinthionen
US4876280A (en) 1988-03-10 1989-10-24 Sandoz Pharm. Corp. Arylcyclohexane and arylcyclohexene analogs of mevalonolactone derivatives and their use
DE3818570A1 (de) 1988-06-01 1989-12-21 Boehringer Mannheim Gmbh Neue 6-substituierte-4-hydroxy-tetrahydro-pyran -2-on-derivate, verfahren zu ihrer herstellung, pharmazeutische praeparate auf basis dieser verbindungen
DE3820177A1 (de) 1988-06-14 1989-12-21 Hoechst Ag Cholestadienderivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel mit hmg-coa-reduktase-hemmender wirkung
EP0422102A4 (en) 1988-06-29 1991-09-11 Merck & Co. Inc. 5-oxa, 5-thia, 5-aza hmg-coa reductase inhibitors
FI893004A (fi) 1988-06-29 1989-12-30 Merck & Co Inc 5-oxygenerade hmg-coa-reduktas -inhibitorer.
US4897402A (en) 1988-06-29 1990-01-30 Merck & Co., Inc. 5-oxa, 5-thia, 5-aza HmG-CoA reductase inhibitors
DE3822650A1 (de) 1988-07-05 1990-02-01 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
US4958839A (en) 1988-07-12 1990-09-25 Guzik Technical Enterprises, Inc. Disc clamp employing resilient cone for spreading balls
US4927944A (en) 1988-08-25 1990-05-22 Bristol-Myers Company Antihypercholesterolemic nitrile compounds
US5011947A (en) 1988-08-25 1991-04-30 Bristol-Myers Antihypercholesterolemic alkylene compounds
US4997658A (en) 1988-11-21 1991-03-05 Merck & Co., Inc. Method for enhancing the lowering of plasma cholesterol levels
US4950675A (en) 1988-12-21 1990-08-21 Warner-Lambert Company Pyridine di-mevalono-lactones as inhibitors of cholesterol biosynthesis
US4957940A (en) 1988-12-21 1990-09-18 Warner-Lambert Company Bicyclo heptane and bicyclo octane substituted inhibitors of cholesterol synthesis
DE3911064A1 (de) 1989-04-06 1990-10-11 Bayer Ag Substituierte 1,8-naphthyridine
CA2016467A1 (en) 1989-06-05 1990-12-05 Martin Eisman Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor
DE3918364A1 (de) 1989-06-06 1990-12-13 Hoechst Ag 3-desmethyl-2-methyl-mevalonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
ATE135352T1 (de) 1989-06-09 1996-03-15 Merck & Co Inc 3-keto-hmg-coa reduktase-inhibitoren
US5010105A (en) 1989-06-09 1991-04-23 Merck & Co., Inc. Antihypercholesterolemic compounds
US5102911A (en) 1989-06-09 1992-04-07 Merck & Co, Inc. 4-Substituted HMG-CoA reductase inhibitors
US4937259A (en) 1989-06-09 1990-06-26 Merck & Co., Inc. Antihypercholesterolemic compounds
EP0408806A1 (en) 1989-07-19 1991-01-23 Merck & Co. Inc. Antihypercholesterolemic agents
US5064856A (en) 1989-07-31 1991-11-12 Merck & Co., Inc. Novel hmg-coa synthase inhibitors
DE3925636A1 (de) 1989-08-03 1991-02-07 Bayer Ag Imino-substituierte pyridine
US4992429A (en) 1989-08-24 1991-02-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel HMG-COA reductase inhibitors
US5023250A (en) 1989-08-24 1991-06-11 Smithkline Beecham Corporation Steroidal 14α-carboxy-alkyl derivatives as regulators of HMG-COA reductase
EP0415488B1 (en) 1989-08-31 1994-04-20 Merck & Co. Inc. 7-Substituted HMG-COA reductase inhibitors
DE3929507A1 (de) 1989-09-06 1991-03-07 Bayer Ag Substituierte amino-pyridine
DE3929913A1 (de) 1989-09-08 1991-04-04 Hoechst Ag 4-hydroxytetrahydropyran-2-one sowie die entsprechenden dihydroxycarbonsaeurederivate, salze und ester, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate sowie vorprodukte
JPH03112967A (ja) 1989-09-26 1991-05-14 Takeda Chem Ind Ltd イソキノロン誘導体
US5025017A (en) 1989-09-28 1991-06-18 E. R. Squibb & Sons, Inc. Seco-mevinic acid derivatives useful as antihypercholesterolemic agents and new intermediates
CA2026389A1 (en) 1989-09-29 1991-03-30 Hideo Nakai Chromene or thiochromene derivatives, process for preparing the same and intermediate therefor
EP0422895A1 (en) 1989-10-10 1991-04-17 Glaxo Group Limited Chemical compounds
EP0424929A1 (en) 1989-10-27 1991-05-02 Takeda Chemical Industries, Ltd. Isoquinolone derivatives, their production and use
US4946860A (en) 1989-11-03 1990-08-07 Rorer Pharmaceutical Corporation Benzothiopyranyl derivatives as HMG-CoA reductase inhibitors
US5110825A (en) 1989-12-28 1992-05-05 Shionogi & Co., Ltd. Benzofuran derivative
US5049577A (en) 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5072023A (en) 1990-02-15 1991-12-10 E. R. Squibb & Sons, Inc. Process for preparing highly substituted phenyls
US5219879A (en) 1990-03-05 1993-06-15 Du Pont Merck Pharmaceutical Company Heterocyclic steroid compounds
US5025000A (en) 1990-03-02 1991-06-18 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitor compounds
US5149834A (en) 1990-03-07 1992-09-22 Fujirebio Inc. 4-hydroxytetrahydropyran-2-one derivatives
WO1991013616A1 (en) 1990-03-08 1991-09-19 Rorer International (Overseas) Inc. NOVEL HMG-CoA REDUCTASE INHIBITORS
US5089523A (en) 1990-05-11 1992-02-18 E. R. Squibb & Sons, Inc. Fluorinated derivatives of mevinic acids
CA2043525A1 (en) 1990-06-24 1991-12-25 Donald S. Karanewsky Phosphorus-containing hmg-coa reductase inhibitors, new intermediates and method
US5128366A (en) 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
MY106564A (en) 1990-07-06 1995-06-30 Squibb & Sons Inc Sulfur-substituted mevinic acid derivatives.
DE4022414A1 (de) 1990-07-13 1992-01-16 Bayer Ag Substituierte pyrrolo-pyridine
CA2050514A1 (en) 1990-09-14 1992-03-15 Bradley C. Pearce Acyclic tocotrienol analogs in the treatment of hypercholesterolemia and hyperlipidemia
JPH1068367A (ja) 1996-08-28 1998-03-10 Usui Internatl Ind Co Ltd 高圧燃料噴射管の接続頭部構造
FR2766819B1 (fr) 1997-07-31 1999-10-29 Pf Medicament Nouvelles sulfonamides derivees d'anilines substituees utiles comme medicaments
US6103487A (en) 1997-08-27 2000-08-15 Merck & Co., Inc. Method of treating cancer
US6586461B1 (en) 1998-06-16 2003-07-01 Wayne State University Prenyl transferase inhibitors
WO2000033826A1 (en) 1998-12-09 2000-06-15 The Arizona Disease Control Research Commission Anticancer agents based on prevention of protein prenylation
US6284910B1 (en) 1998-12-15 2001-09-04 University Of Kentucky Research Foundation Farnesyl pyrophosphate analogs
AU3390000A (en) 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU3248600A (en) 1999-03-03 2000-09-21 Merck & Co., Inc. Inhibitors of prenyl-protein transferases
FR2819509B1 (fr) 2001-01-18 2004-04-16 Servier Lab Nouveaux composes cycloheptene, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU2002355739A1 (en) 2001-07-30 2003-02-17 University Of Southern California Preparation and use of alpha-keto phosphonates
ATE447955T1 (de) 2001-08-24 2009-11-15 Univ Yale Piperazinon-verbindungen als antitumorale und krebsbekämpfende mittel
WO2006039721A2 (en) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
US8012949B2 (en) 2004-10-08 2011-09-06 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including FPPS, GGPPS, and DPPS
US8669253B2 (en) 2006-03-14 2014-03-11 Duke University Methods for treating glaucoma and macular degeneration
JP2009530414A (ja) 2006-03-17 2009-08-27 ザ ボード オブ トラスティーズ オブ ザ ユニヴァーシティー オブ イリノイ ビスホスホネート化合物及び方法
JP2009530392A (ja) 2006-03-22 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティー オブ カリフォルニア タンパク質プレニルトランスフェラーゼの阻害剤
TW200806284A (en) 2006-03-31 2008-02-01 Alcon Mfg Ltd Prenyltransferase inhibitors for ocular hypertension control and the treatment of glaucoma
US7781418B2 (en) 2006-12-14 2010-08-24 Isis Innovation Ltd. Composition for treating bone disorders
US20080200679A1 (en) 2007-01-22 2008-08-21 University Of Southern California Alpha-HYDROXY, alpha-SUBSTITUTED METHYLENEBISPHOSPHONATES AND PHOSPHONOACETATES
US7977323B2 (en) 2007-11-30 2011-07-12 Novartis Ag C2-C5-alkyl-imidazole-bisphosphonates
AU2009218468A1 (en) 2008-02-28 2009-09-03 Novartis Ag Quinolines as inhibitors of farnesyl pyrophosphate synthase
US20090311237A1 (en) 2008-04-14 2009-12-17 Frost Gregory I Combination therapy using a soluble hyaluronidase and a bisphosphonate
US20110178138A1 (en) 2008-07-28 2011-07-21 The Regents Of The University Of California Inhibitors of protein prenyltransferases
KR20110079813A (ko) 2008-09-22 2011-07-08 아이시스 이노베이션 리미티드 이미다조〔1,2－α〕피리디닐 비스포스포네이트
EP2344503B1 (en) 2008-09-22 2014-04-16 Isis Innovation Ltd 5-azaindole bisphosphonates
WO2010033980A2 (en) 2008-09-22 2010-03-25 Isis Innovation Ltd. 4-azaindole bisphosphonates
CN102186803A (zh) 2008-10-13 2011-09-14 诺瓦提斯公司 为法尼基焦磷酸合酶活性抑制剂的水杨酸衍生物
WO2010088457A2 (en) 2009-01-29 2010-08-05 H. Lee Moffitt Cancer And Research Institute, Inc. Methods for inducing tumor regression, inhibiting tumor growth, and inducing apoptosis in breast tumors with geranylgeranyltransferase i inhibitors
WO2012034038A2 (en) 2010-09-09 2012-03-15 H. Lee Moffitt Cancer Center And Research Institute, Inc. Dual inhibitors of farnesyltransferase and geranylgeranyltransferase i
KR20200060540A (ko) 2015-09-09 2020-05-29 칭화 유니버시티 고-효율 백신 아쥬반트로서 메발로네이트 경로 억제제

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130195919A1 (en) * 2010-03-05 2013-08-01 President And Fellows Of Harvard College Induced dendritic cell compositions and uses thereof
US20130309270A1 (en) * 2010-10-22 2013-11-21 President And Fellows Of Harvard College Vaccines comprising bisphosphonate and methods of use thereof

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
FRANCESCA FIORE 等: "Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid", 《BLOOD》, vol. 110, no. 3, 1 August 2007 (2007-08-01), pages 921 - 927, XP002694502, DOI: 10.1182/blood-2006-09-044321 *
FRANCESCA FIORE 等: "Enhanced ability of dendritic cells to stimulate innate and adaptive immunity on short-term incubation with zoledronic acid", vol. 110, no. 3, pages 921 - 927, XP002694502, DOI: 10.1182/blood-2006-09-044321 *
GEORG GRUENBACHER等: "IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells", 《CANCER RES.》, vol. 70, no. 23, 31 December 2010 (2010-12-31), pages 9611 - 9620 *
GEORG GRUENBACHER等: "IL-2 costimulation enables statin-mediated activation of human NK cells, preferentially through a mechanism involving CD56+ dendritic cells", vol. 70, no. 23, pages 9611 - 9620 *
HIRAGA, TORU等: "Effects of oral UFT combined with or without zoledronic acid on bone metastasis in the 4T1/luc mouse breast cancer", vol. 106, pages 973 - 979, XP071281314, DOI: 10.1002/ijc.11330 *
LALE ATAHAN等: "Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study", vol. 18, pages 691 - 698, XP019850906 *
LARA LACERDA等: "Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation", vol. 3, pages 849 - 856 *
XIAOSAN SU等: "Coculturing dendritic cells with zoledronate acid efficiently enhance the anti-tumor effects of cytokine-induced killer cells", 《J. CLIN. IMMUNOL.》, vol. 30, no. 5, 15 June 2010 (2010-06-15), pages 766 - 774, XP019822507 *
何金花等: "辛伐他汀联合5-ＦＵ对Ｋ562细胞增殖及凋亡的影响", vol. 29, no. 6, pages 578 - 582 *
张福成等: "双膦酸盐抗肿瘤作用机制的研究进展", 《中国医院药学杂志》, vol. 28, no. 18, 30 September 2008 (2008-09-30), pages 1590 - 1593 *
沈倍奋: "肿瘤生物治疗的抗体研究进展", vol. 22, no. 2, pages 166 - 169 *
罗清琼等: "他汀类药物对免疫细胞功能的调节作用及机制", 《免疫学杂志》, vol. 25, no. 2, 31 March 2009 (2009-03-31), pages 222 - 224 *
郑龙志等: "他汀类药物抗肿瘤作用的研究进展", 《医学综述》, vol. 12, no. 10, 31 May 2006 (2006-05-31), pages 605 - 607 *

Also Published As

Publication number Publication date
KR20200066690A (ko) 2020-06-10
EP3698797A1 (en) 2020-08-26
US20210008084A1 (en) 2021-01-14
WO2019076269A1 (zh) 2019-04-25
CN111225672B (zh) 2023-09-29

Similar Documents

Publication Publication Date Title
JP7098748B2 (ja) Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する２’３’環状ジヌクレオチド
JP7037667B2 (ja) Ｓｔｉｎｇアダプタータンパク質を活性化するホスホン酸結合を有する３’３’環状ジヌクレオチド
RU2729936C2 (ru) Противораковое средство
WO2017041720A1 (zh) 作为高效的疫苗佐剂的甲羟戊酸通路的抑制剂
JP2021020921A (ja) 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
US20230029213A1 (en) Crystalline Forms and Salt Forms of a Kinase Inhibitor
JP7296398B2 (ja) ３’３’－環状ジヌクレオチド
WO2018181420A1 (ja) ワクチンアジュバント製剤
TW201934128A (zh) 活化sting轉接蛋白之具有膦酸酯鍵之2’2’環二核苷酸
CA3220923A1 (en) Diacylglyercol kinase modulating compounds
US20240065987A1 (en) Anti-cancer activity of adamantane derivatives
US20230046340A1 (en) Diacylglyercol kinase modulating compounds
CN113939503A (zh) 激酶抑制剂的结晶盐形式
JP7326321B2 (ja) ２’３’－環状ジヌクレオチド
CN113543851A (zh) 2’3’-环二核苷酸及其前药
CN111225672B (zh) 甲羟戊酸通路抑制剂及其药物组合物
TW202340148A (zh) 激酶抑制劑之結晶形式及鹽形式
TW202100162A (zh) 包含碳環核苷酸之３’３’－環二核苷酸
JP2022522914A (ja) 医学的使用
WO2019241536A1 (en) Oxabicycloheptanes for enhancing car t cell function
WO2024048541A1 (ja) 癌の治療及び／又は予防のための医薬品
Mitra et al. Differential CD40/CD40L Expression Results

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant